NVAX — NOVAVAX INC

—
Nasdaq · Health Care · Biotechnology · CIK 1000694 ·
Last close
$10.63
Market Cap
$1.75B
52W High
$11.97
52W Low
$6.20
ADV30
5,672,660
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 56,698,000 42,452,000 -54,906,000 -53,387,000 955,575,000 191,458,000 1,146,282,000
Mar 2026 139,514,000 108,819,000 -15,430,000 -9,491,000 1,043,162,000 228,363,000 1,187,924,000
Dec 2025 147,139,000 125,035,000 15,037,000 17,527,000 1,176,512,000 240,634,000 1,304,265,000
Sep 2025 70,445,000 48,949,000 -80,980,000 -202,379,000 1,179,889,000 268,023,000 1,336,561,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-91,556,000
Investing CF
$-33,309,000
Financing CF
$72,473,000
CapEx
$-6,063,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.58
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-4,631,026,000
Inventory
$10,006,000
Receivables
$18,739,000
ST Investments
$527,882,000
EBIT TTM
$-223,419,000
Pretax Income TTM
$-245,315,000
Interest Exp TTM
$21,896,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$413,796,000
EBITDA
$-101,552,000
Free Cash Flow
$153,394,432
Enterprise Value
$1,131,767,680
Total Cash
$719,340,032
Total Debt
$297,319,008
Shares Out
164,945,726
Trailing EPS
$-1.53
Book Value
$-1.16
ROE
—
ROA
-6.5%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,123,479,000 550,640,000 440,302,000 1,176,512,000 1,304,265,000 -127,753,000 -244,635,000
Dec 2024 682,162,000 -248,931,000 -187,499,000 1,560,418,000 2,184,259,000 -623,841,000 -87,263,000
Dec 2023 556,382,000 -566,511,000 -545,062,000 1,797,490,000 2,514,417,000 -716,927,000 -713,967,000
Dec 2022 1,598,951,000 -644,736,000 -657,939,000 2,258,679,000 2,892,757,000 -634,078,000 -415,937,000

TTM Snapshot

Revenues TTM
$1,184,919,000
NetIncome TTM
$-743,120,000
OpCashFlow TTM
$0
Assets (Latest)
$1,560,418,000
Forward EPS
$-0.61

Max Pain — expiry 2026-10-16

max pain strike: $7.00 · spot: $10.55 · call oi: 23,757 · put oi: 3,718
Expected Move to 2026-10-16: ±$1.19 (11.28%) — implied range $9.36 – $11.74 · ATM straddle on $10.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VIR Vir Biotechnology, Inc. $1.80B $10.66 —
COAG Hemab Therapeutics Holdings, Inc. $1.62B $34.74 —
IMCR Immunocore Holdings plc $1.58B $30.72 —
MESO MESOBLAST LTD $1.96B $15.12 —
RXRX RECURSION PHARMACEUTICALS, INC. $2.00B $3.74 —

News headlines (Yahoo Finance, 1h cache)

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
2026-09-28 12:00 · Yahoo
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
2026-09-18 21:45 · Yahoo
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?
2026-09-18 07:45 · Yahoo
Novavax (NVAX) Could Be 32% Above Fair Value On Medicare Policy Fears
2026-09-16 07:12 · Yahoo
Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?
2026-09-16 05:13 · Yahoo
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
2026-09-15 13:00 · Yahoo
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
2026-09-10 18:02 · Yahoo
Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference
2026-09-10 05:02 · Yahoo
Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
2026-09-07 11:02 · Yahoo
Novavax to Participate in September Investor Conferences
2026-09-02 21:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.